In silico assessment of cyanobacterial alkaloids as probable medications against SARS-CoV-2

Key Points

• Cyanobacterial alkaloids show potential bioactivity against SARS-CoV-2, indicating possible therapeutic applications.
• Molecular docking studies provided significant insights, with top candidates demonstrating high affinity, such as 9.3 kcal/mol.
• Assessing the bioactivity using in silico methods allowed for a systematic evaluation of potential interventions.
• Further validation in clinical settings is needed to confirm efficacy and safety in human populations.